- Home
- DGHI vs MNOV Comparison
DGHI vs MNOV Comparison
Compare DGHI & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGHI
- MNOV
- Stock Information
- Founded
- DGHI 2017
- MNOV 2000
- Country
- DGHI United States
- MNOV United States
- Employees
- DGHI N/A
- MNOV N/A
- Industry
- DGHI Finance: Consumer Services
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- DGHI Finance
- MNOV Health Care
- Exchange
- DGHI Nasdaq
- MNOV Nasdaq
- Market Cap
- DGHI 90.1M
- MNOV 91.7M
- IPO Year
- DGHI N/A
- MNOV 2005
- Fundamental
- Price
- DGHI $2.99
- MNOV $1.90
- Analyst Decision
- DGHI Strong Buy
- MNOV Strong Buy
- Analyst Count
- DGHI 1
- MNOV 1
- Target Price
- DGHI $2.50
- MNOV $9.00
- AVG Volume (30 Days)
- DGHI 874.7K
- MNOV 21.3K
- Earning Date
- DGHI 04-02-2025
- MNOV 02-18-2025
- Dividend Yield
- DGHI N/A
- MNOV N/A
- EPS Growth
- DGHI N/A
- MNOV N/A
- EPS
- DGHI N/A
- MNOV N/A
- Revenue
- DGHI $42,146,057.00
- MNOV N/A
- Revenue This Year
- DGHI N/A
- MNOV N/A
- Revenue Next Year
- DGHI N/A
- MNOV N/A
- P/E Ratio
- DGHI N/A
- MNOV N/A
- Revenue Growth
- DGHI 100.56
- MNOV N/A
- 52 Week Low
- DGHI $0.84
- MNOV $1.12
- 52 Week High
- DGHI $3.77
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- DGHI 61.88
- MNOV 45.15
- Support Level
- DGHI $2.81
- MNOV $1.87
- Resistance Level
- DGHI $3.17
- MNOV $2.06
- Average True Range (ATR)
- DGHI 0.49
- MNOV 0.08
- MACD
- DGHI 0.02
- MNOV 0.00
- Stochastic Oscillator
- DGHI 62.22
- MNOV 47.48
About DGHI Digihost Technology Inc. Common Subordinate Voting Shares
Digihost Technology Inc is a blockchain company focused on Bitcoin mining. The company's mining facility is located in Buffalo, New York, and is equipped with an 18.7 MVA 115,000-kilovolt ampere outdoor substation with an option to increase the power output to 42MVA.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.